OXFORD

Targeting the high affinity receptor, FcγRI, in autoimmune disease, neuropathy, and cancer

Tosca Holtrop[1], Kevin Budding[1], Arianne M. Brandsma[2] and Jeanette H.W. Leusen[1,*] (iD)

[1]Immunotherapy Laboratory, Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands and
[2]Princess Máxima Center for Pediatric Oncology and Oncode Institute, Utrecht, The Netherlands

*Correspondence: University Medical Center Utrecht, Center for Translational Immunology (CTI), Section Applied, HP F03.281, Room G03.555, Laboratory for Immunotherapy, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Tel: +31 88 7554268; Fax: +31 88 7554305; Email: jleusen@umcutrecht.nl

Introduction

Fc gamma receptors (FcγRs) are transmembrane proteins that bind to the Fc tail of IgG antibodies. They are required for cellular effector functions of antibodies, including direct neutralization of pathogens, recruitment of the complement system to directly lyse pathogens or infected cells, and cellular effector functions including phagocytosis and antibody-dependent cellular cytotoxicity/phagocytosis (ADCC/ADCP) [1, 2]. As many FcRs are mostly expressed on innate immune cells [3], they serve as a vital connection between the cellular and humoral parts of the immune system, connecting antigen-specific interactions of antibodies to non-specific effector mechanisms of FcR-bearing cells.

FcγR activation is tightly regulated to prevent immune responses by non-antigen-bound antibodies, or in the absence of other 'danger signals' (e.g. cytokines). For example, most FcγRs recognize IgG with low affinity, but can bind immune complexes (ICs), like opsonized pathogens, with high avidity [4]. FcγRI is the only FcγR with a high affinity for IgG. Because of its high affinity, FcγRI is constitutively saturated with monomeric IgG, even after isolation or extravasation of immune cells, but it does not lead to intracellular signaling and subsequent effector functions [1]. This led to the dogma that this receptor played no role in immune responses, resulting in FcγRI to be much less studied than the low affinity FcγRs. However, several studies demonstrated that FcγRI does play a significant part in inflammation, autoimmunity, and neuropathy, as well in antibody-therapy in tumor models [5–9].

FcγRI saturated with pre-bound IgG is able to effectively bind ICs after cytokine stimulation [10]. This process is called 'inside-out signaling', as the ligand binding capacity of the receptor is rapidly enhanced after intracellular signaling without affecting the receptor expression. This process is also described for integrins [11], as well as for FcαRI and FcγRIIa [12, 13]. Stimulation with cytokines strongly enhances IC binding, resulting in stronger cellular effector functions such as ADCC [10, 14]. Moreover, therapeutic antibodies that bind to FcγRI can also benefit from cytokine stimulation, leading to improved tumor killing [12, 15, 16].

In this review, we will discuss FcγRI interactions with IgG and ICs, as well as how to enhance FcγRI cellular effector functions via inside-out signaling. Additionally, this review will focus on how therapeutic antibodies targeting FcγRI, possibly in combination with inside-out signaling, can be turned into novel therapeutic strategies to treat human autoimmune and malignant diseases.

The high affinity IgG receptor FcγRI

The affinities and specificities for the different IgG subclasses vary considerably within the FcγR family (e.g. FcγRI, FcγRIIa, FcγRIIb, and FcγRIII). Only FcγRI binds with high affinity to human IgG, and binds exclusively to IgG1, IgG3, and IgG4, not IgG2 [4, 17]. This high affinity binding is cross-species, as also rabbit IgG and mouse IgG2a and IgG2c can bind to human FcγRI with high affinity [18–20]. Likewise, mouse FcγRI is also a high affinity receptor for mouse IgG2a, which is a functional homologue of human IgG1 [21], as well as for human and rabbit IgG [19, 22].

FcγRI consists of three extracellular domains, a transmembrane part, and an intracellular tail (FcγRI-CY) (Fig. 1A). Extracellular domains one (EC1) and two (EC2) are homologous to those found in other FcγRs, but EC3, which bridges EC2 with the transmembrane part of the receptor, is unique to FcγRI [23]. The transmembrane part is responsible for FcR γ-chain association, and the α-chain of the receptor has an intracellular tail [24]. The interaction between IgG and FcγRI lies within two binding sites of the EC2 domain (Fig. 2A). The binding of the Fc-tail to these two sites occurs in an asymmetric manner: to engage the receptor, the Fc-tail

Fig. 1. Schematic representation of FcγRI and FcγRI functions. (A) Schematic representation of FcγRI with three extracellular domains; EC1, EC2, and EC3, the transmembrane part and intracellular tail (FcγRI-CY). The γ-chain and α-chain are responsible for different actions of the receptor. (B) FcγRI functions are regulated on multiple levels [1]. Interaction of FcγRI with monomeric IgG leads to rapid internalization and recycling of the receptor-IgG complex to the plasma membrane [2]. Crosslinking of FcγRI by ICs induces immunoreceptor tyrosine-based activation motif (ITAM) signaling via FcRγ and internalization and degradation of the antigen-receptor complex in the lysosome. The degraded peptides can be presented on MHC class I (MHC I) or MHC class II (MHC II), which leads to T cell activation.

must use a different set of residues from each chain of the homodimer [17]. Binding to site 1 is governed by the insertion of Leucine235 (Fig. 2B), while binding to site 2 involves a relatively flat interaction surface and does not involve a local conformational change (Fig. 2C). Leucine235, as well as the critical residues 233 and 234, on IgG-Fc has been identified to be crucial for binding to FcγRI [17, 25]. These critical residues are changed in IgG2, explaining why this antibody cannot bind to FcγRI [17].

It was proposed that the high affinity of FcγRI was due to the extra EC3 domain [23], which was supported by studies that switched the extracellular domains of FcγRI with extracellular domains of low affinity FcγRs [23, 26]. However, the crystal structure of FcγRI indicated that EC3 is located distally from the IgG binding site in EC2 [27]. As a result, EC3 is unlikely to come into direct contact with IgG, although it may promote high affinity binding by stabilizing the IgG binding conformation or extending the receptor into the extracellular space [17, 27]. Also, studies on the affinity of recombinant FcγRI lacking EC3 show that the effect of EC3 on high affinity binding is relatively minor [23].

Several studies now show that the EC2 domain converts the high affinity binding of FcγRI [17, 27]. Because of a deletion of one amino acid, the FG-loop, which is present in one of the two binding sites of EC2, is shorter in FcγRI than in the other FcγRs. This deletion may reduce steric hindrance for IgG. This deletion also revealed a unique hydrophobic pocket in EC2 of FcγRI, which perfectly suited the residue Leu235 of the Fc-tail, explaining the high affinity [17] (Fig. 2B). Additionally, the FG-loop within EC2 has been demonstrated to interact with glycans on the Fc-tail of IgG, which is unique for FcγRI [28].

Binding of monomeric IgG to FcγRI does not lead to intracellular signaling and subsequent FcγRI activation, but it

does facilitate receptor-mediated endocytosis and recycling [23, 29, 30] (Fig. 1B). Monomeric IgG binding to FcγRI likely creates a threshold for IC, allowing only large ICs or many smaller complexes to displace monomeric IgG. Studies with FcγRI knock-out mice, as well as biochemical studies investigating IC binding, show that FcγRI does significantly bind and respond to ICs of various sizes [5, 20, 31]. FcγRI effector responses include bacterial clearance, inflammation, anaphylaxis, endocytosis, phagocytosis, antigen presentation, release of B-cell stimulating factors, and anti-tumor responses [5, 6, 20, 32].

FcγRI expression and signaling

FcγRI is constitutively expressed on most myeloid cells, including macrophages, monocytes, and dendritic cells, and can be induced by cytokines on neutrophils, mast cells, and eosinophils [3]. FcγRI is also inducible on endothelial cells [33] and neurons [34]. Besides FcγRI, effector cells express other FcγRs that can bind to ICs as well.

FcγRI expression can be upregulated by cytokines. For example, FcγRI expression on dendritic cells and monocytes can be increased by pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) [10, 35]. Anti-inflammatory cytokines, like transforming growth factor beta (TGF-β), IL-4, and IL-10 can decrease FcγRI expression while increasing expression of the inhibitory FcγRIIb. By altering expression levels of FcγRI, the immune response can be regulated, as an increased number of receptors can bind more ligand.

FcγRI signals via the immunoreceptor tyrosine-based activation motif (ITAM), which is located on the γ-chain (Fig. 1). The ligand-binding domain of FcγRI can interact with ICs, such as antibody-opsonized pathogens or tumor cells

Fig. 2. Schematic representation of Fc-FcγRI interaction. (A) Extracellular domains EC1, EC2, and EC3 are depicted in cyan, purple, and blue, respectively. The Fc-tail of the antibody is depicted in grey. CH stands for constant heavy chain, CL for constant light chain, VL for variable light chain, and VH for variable heavy chain. Orange dashed boxes indicate binding sites 1 and 2. (B) Detailed depiction of binding site 1 (FcγRI and Fc-chain). The surface of EC2 is shown in purple and the surface of EC1 in cyan. The residues of the Fc-chain involved in the interaction of FcγRI are represented with lines (grey = Fc-chain, yellow = carbon, red = oxygen, and blue = nitrogen). The blue dashed line represents the hydrophobic pocket where Leu235 can bind. (C) Detailed depiction of binding site 2. The same color scheme as in (B) is used. Here the interaction surface lies relatively flat. For additional details see review by Kiyoshi *et al.* [17].

[20, 31, 36]. After cross-linking the ligand-binding EC2 by ICs, the tyrosine residues of the ITAM can be phosphorylated by kinases of the SRC family [1]. These phosphotyrosines serve as a docking site for SYK kinases, which bind via their SH2 domains and are activated upon binding [5]. SYK activation results in the activation of the RAS-MAPK pathway, increased intracellular calcium levels, and eventually activation of NF-κB transcription factors through induction of multiple downstream targets [37]. These signals activate immune cells, resulting in phagocytosis, oxidative burst, and cytokine release [24, 37]. However, cross-linking of the inhibitory FcγRIIb causes LYN to phosphorylate the immunoreceptor tyrosine-based inhibitory motif (ITIM), which recruits and activates the SH2-containing phosphatases SHIP and SHP1 [38, 39]. Subsequently, the kinases downstream of ITAM signaling will be dephosphorylated by these phosphatases. This can suppress FcγRI effector functions by balancing the activating signaling cascades.

Immunomodulatory effects are mainly regulated via the single inhibitory receptor, FcγRIIb. However, recent studies have shown that the activating FcγRI and FcγRIIa can also produce inhibitory signals [40–43]. FcγRI engagement along with phagocytic signaling may facilitate inhibitory functions, including secretion of IL-10, reducing pro-inflammatory cytokine production, and reducing T-cell proliferation [44]. Upon IC binding to FcγRI, it is possible that IL-10 secretion affects the macrophage response, leading to both augmenting FcγRI

and altering the status of the macrophage and subsequently the outcome of the FcγRI engagement. IC-mediated signaling by FcγRI can also inhibit IFN-γ signaling events [45]. This points to an IC-mediated inhibition of IFN-γ signaling that involves the ITAM-containing FcγRI as well as the ITIM-dependent phosphatase SHP-1, thereby effectively suppressing STAT1 phosphorylation. Studies using various FcR-blocking antibodies in FcR γ-chain knockout mice and FcγRI−/− mice confirmed that the FcγRI mediates these suppressive effects [5, 6, 46]. However, more research is needed to better understand the possible inhibitory signals of FcγRI.

Inside-out signaling on FcγRI regulation

Since triggering of FcR leads to strong effector responses and potential cytokine storms, these receptors need to be tightly regulated. An example of regulation is that only clusters of immunoglobulins can activate low affinity receptors. For FcγRI this is regulated differently; the receptor function is always blocked by its ligand IgG, and the receptor can only be activated with a proper second signal. FcγRI, like integrins, is under ' inside-out' signaling, which means that binding of a cytokine to a cytokine receptor can change FcγRI so that it can bind and respond to ICs even when saturated with monomeric IgG [10, 12, 14] (Fig. 3.I). TNF-α and IFN-γ, can rapidly enhance the IC binding capacity and subsequent effector

Fig. 3. Role of FcγRI in autoimmune diseases and possible clinical applications for targeting FcγRI. Numbers depict autoimmune diseases and Roman numerals the possible intervention techniques [1]. In SLE, IgG autoantibodies are produced against self-antigens, which opsonize late apoptotic cells. Blocking FcγRI (not depicted) increases phagocytosis of apoptotic cells [2, 47]. ICs, formed by autoantibodies and self-antigens, reside in the kidney, causing the infiltration of FcγRI-expressing monocytes and macrophages, which release pro-inflammatory cytokines and chemokines, leading to inflammation and subsequently LN [3]. In ITP, IgG autoantibody-coated platelets get cleared by FcγRI-expressing macrophages and blocking FcγRI reduced clearance by 50% [20] (not depicted) [4]. In atopic dermatitis, FcγRI expression is increased on M1 macrophages, making them readily bind to the increased total and antigen-specific serum IgG4 [48]. FcγRI-targeted immunotoxins alter the polarization towards M2 phenotype [5, 49]. In RA, IgG autoantibody ICs can bind macrophages and neutrophils causing the release of pro-inflammatory cytokines which increase inflammation and RA morbidity. The IgG-ICs also translocate to the joints, causing further inflammation. They can also directly bind to osteoclasts. Capturing the IgG-ICs with recombinant soluble FcγRs (III) reduces cartilage degradation (not depicted) [6, 50, 51]. Activation of FcγRI on DRG neurons caused increased neuron excitability and subsequent pain. Blocking the receptor relieved pain in mice [52, 53]. (I) Cytokines cause inside-out signaling, leading to enhanced clustering of FcγRI in the membrane. Cytokines also regulate expression of FcγRI by inducing transfer of intracellular FcγRI to the plasma membrane as well as *de novo* expression. (II) bsAbs can be engineered to bind FcγRI-expressing target cells and a tumor-target, thereby inducing tumor-killing [54–56]. (III) Recombinant soluble FcγR can 'capture' circulating ICs. SLE = systemic lupus erythematous, LN = lupus nephritis, ITP = immune thrombocytopenic purpura, RA = rheumatoid arthritis, and bsAbs = bispecific antibodies.

functions, without altering FcγRI surface expression levels, and affecting affinity for monomeric IgG [10].

Two mechanisms have been proposed by which cytokine stimulation enhances the binding capacity of FcγRI: increased clustering of the receptor and/or a conformational change of FcγRI. First, FcγRI, which is normally found in lipid rafts [57], becomes more clustered in the plasma membrane in response to cytokine stimulation, increasing its avidity [23, 58]. This was demonstrated by super resolution imaging, which revealed that cytokines influence the cluster size of FcγRI in Ba/F3-FcγRI cells [14]. This process is dependent on an intact actin cytoskeleton, and the involvement of the serine/threonine phosphatase PP1 (protein phosphatase 1), while the phosphorylation of FcγRI-CY itself is unaffected [14]. This in contrast to FcγRI crosslinking (outside-in signaling), where all four serines in the CY domain of FcγRI need to be dephosphorylated upon crosslinking to lead to phagocytosis [59]. Interestingly, okadaic acid, which is a phosphatase

inhibitor of PP2 at low concentrations and PP1 at higher concentrations, prevents the dephosporylation of these serines in outside-in signaling, while it does not directly influence FcγRI phosphorylation in inside-out signaling [14, 60]. Second, a change in FcγRI conformation may increase its binding capacity and affinity for IC. In outside-in signaling, dephosphorylation changes the charge of FcγRI-CY, resulting in a conformational change. This is accompanied by a conformational change in the transmembrane domain and, ultimately, in one or more extracellular domains [61]. FcγRI crystallization revealed that when IgG binds, the EC1 and EC2 domains rotate 19 degrees with respect to the EC3 domain [10]. This rotation could lead to a conformation change of the receptor that alters the affinity of FcγRI for ICs. If the rotation tilts the EC2 domain, there may be more space for an IC to bind to multiple FcγRI molecules. Future research may reveal if increased FcγRI clustering after cytokine stimulation correlates with a conformational change of the receptor.

The implications of FcR inside-out signaling in the treatment of patients with therapeutic antibodies is still under investigation. Activating inside-out signaling could be advantageous to increase the clinical efficacy of therapeutic antibodies. However, FcRs also play a role in the clearance of target–antibody complexes via endocytosis and subsequent degradation in the lysosomal compartment [12]. In these cases, it might be beneficial to inhibit FcRs with antagonistic cytokines to preserve sufficient therapeutic doses of the antibodies, ultimately allowing for lower antibody administration or maintenance doses [62]. Taking advantage of FcR inside-out signaling will ultimately depend on the requirements of the effector cells needed, which FcR they express, and the mode(s) of action of the therapeutic antibodies [62]. This complexity should be taken into account to optimize the therapeutic effectiveness of existing and new antibodies.

Clinical applications of FcγRI

Antibody therapy

There is an increasing evidence that FcRs play a significant role in the induction and maintenance of pathological inflammatory responses induced by ICs, especially autoantibody ICs [47, 63]. The balance between 'activating' and 'inhibitory' roles of FcRs modulates FcR-dependent antibody effector responses in normal immunity [64]. Deviation towards activating functions of FcγRs, as seen in some autoimmune diseases, will reduce the threshold for IC-mediated activation of inflammatory cells, leading to inflammation and tissue damage [2, 64]. Murine FcγRI has been implicated in a number of monoclonal antibody (mAb)-mediated disease models [6, 7, 65] and mAb therapy showed the potency of FcγRI in eliciting mAb-mediated effector responses [36] (Fig. 3).

Antibodies are of interest in immunotherapy due to their high target specificity. Binding of specific antigens is possible through the variable region located in the antigen-binding fragment (Fab), while the non-variable Fc tail can simultaneously bind to FcγRI. The Fab domain of FcγRI can interact with ICs, such as antibody-opsonized pathogens or tumor cells, resulting in antigen internalization or blockade of signal transduction pathways [20, 31, 36]. Strategies for targeting FcγRI, inducing direct Fc blocking, and overcoming IC-mediated autoimmune disorders, are all part of the advancement of therapeutics for the treatment of inflammation [5, 66].

Autoimmune diseases

The pathogenic effects of systemic autoimmune diseases are thought to be triggered by the development of autoantibodies and subsequent IC deposition in tissues [67]. Autoantibodies cause inflammation in antibody-dependent autoimmunity syndromes including immune thrombocytopenic purpura (ITP), systemic lupus erythematosus (SLE), and arthritis by binding to FcγRs [67–70]. In several chronic inflammatory diseases increased expression of FcγRI on M1 macrophages has been observed. Targeting FcγRI with mAbs that block the receptor showed promising results in inducing elimination of the disease-causing M1 macrophage population, while leaving the M2 anti-inflammatory population intact, even though both express FcγRI [49].

Atopic dermatitis is an allergic skin disease characterized by increased levels of total and antigen-specific serum IgE and IgG4 [48]. In both the acute and chronically inflamed skin, FcγRI expression levels are increased, which probably results from upregulation of the receptors on macrophages [48]. *In vitro* and *in vivo* studies showed that FcγRI-targeted immunotoxins can effectively eliminate murine and human M1 macrophages with high specificity [49]. This elimination alters the micro-environment, favoring polarization towards the M2 phenotype. FcγRI-targeted therapeutics can thus be a powerful tool for both identifying M1 macrophages *in vivo* and reversing M1-associated chronic disease (Fig. 3.4).

ITP is an autoimmune disease characterized by low platelet counts caused by autoantibody-mediated clearance of platelets, which results in easy bruising and increased bleeding. Here, FcγRI-expressing macrophages seem to play an essential role in this chronic disease, where they contribute to platelet clearance (Fig. 3.3). Using an anti-FcγRI antibody, platelet clearance could be reduced by 50% [20]. In mouse models, ITP could only be prevented by combining blocking antibodies for FcγRI and FcγRIV, the latter being a murine specific Fc-receptor. Nonetheless, the use of an anti-FcγRI mAb (clone 197) in a chronic ITP patient resulted in clinical improvement by preventing FcγRI mediated destruction of IgG-coated platelets [71].

SLE is a non-organ specific autoimmune disease in which IgG autoantibodies are produced against a wide range of self-antigens [68]. One pathogenic factor in SLE is the opsonization of late apoptotic cells by autoantibodies, resulting in decreased FcγRI-mediated clearance of apoptotic cells by phagocytes [47]. IgG autoantibodies may bind to molecules on apoptotic cells that are required for recognition and facilitation of macrophage uptake, such as phosphatidylserine or C1q [72–74]. Intracellular autoantigens may become exposed, in altered or unaltered form, at the outer surface of apoptotic cells during the apoptotic process [75, 76]. Decreased clearance of apoptotic cells results in prolonged exposure of these cell surface-expressed autoantigens to the immune system, which may explain the development of autoantibodies against these intracellular antigens. In part, this is due to increased signaling caused by IgG binding to FcγRs, which may affect the ability of monocyte-derived macrophages to internalize apoptotic cells [47, 77]. Fc receptor blockade, with the partial blocking anti-FcγRI antibody 10.1 (see Limitations section), significantly reduced phagocytosis inhibition [47]. This effect was amplified when anti-FcγRI antibody was combined with anti-FcγRIII blocking antibody (3G8) on macrophages, and it abolished the inhibitory effect of SLE autoantibodies [47].

The formation of ICs between autoantibodies and self-antigens has also been linked to the development of lupus nephritis (LN) [68, 78]. In the kidneys, the presence of ICs activates monocytes and macrophages by interacting with FcγRI and FcγRIII, triggering an inflammatory cascade of cytokines and chemokines. Monocytes secrete monocyte chemoattractant protein 1 (MCP-1) [79], which recruits macrophages but may also promote a further influx of monocytes into the kidney. The greater ability of monocytes to migrate and secrete MCP-1 is linked to increased FcγRI expression on the cell surface, especially in LN patients [79], and also with markers of impaired renal function. This could lead to a vicious cycle of renal inflammation and facilitate the infiltration of monocytes to sites of IC deposition in the kidney [80], which eventually could result in permanent tissue damage [81]. FcγRI is critical for the development of LN, as mice with gamma chain-deficient FcγRI forming and depositing ICs were surprisingly protected from severe nephritis [67]. Taken

together, these data suggest an important role for FcγRI in the pathogenesis of both SLE and LN and blocking FcγRI seems to increase the clearance of apoptotic cells, but this warrants further research (Fig. 3.1 and 3.2).

The most common form of autoimmune inflammatory arthritis is rheumatoid arthritis (RA), which affects up to 1% of the human population [82]. The pathogenesis of RA has been linked to IgG-IC/FcγRI signaling [50–52, 66, 83] and FcγRI expression levels correlate with disease progression [6]. When compared to total serum IgG1, RA-specific autoantibodies show differences in Fc-linked galactosylation and fucosylation. These IgG1 changes resulted in decreased affinity for FcγRIIIa and FcγRIIb, but not for FcγRI, which could increase the availability of RA-specific autoantibodies to bind and activate FcγRI [84]. In collagen-induced arthritis (CIA) and antigen-induced arthritis (AIA) models, FcγRI-deficient mice showed reduced arthritic symptoms [50, 66, 83], and treatment with a FcγRI-directed immunotoxin reduced inflammation and bone degradation in human FcγRI–transgenic rats with joint inflammation [85]. In another AIA model, deletion of the FcγRI α-chain was partially protective, but it also impaired their ability to clear infection with *Bordetella pertussis* [6]. Additionally, IgG autoantibody ICs can bind to neutrophils, macrophages, and monocytes, causing pro-inflammatory cytokine release and aggravating inflammation, contributing to RA morbidity. In RA patients, IgG-IC was present in high concentrations in the serum and infected joints, making it an important pathological characteristic of the disease [50, 86]. IgG-autoantibodies can directly bind to pre-osteoclasts and induce differentiation, as well as activate mature osteoclasts [69]. Interestingly, in AIA and CIA models, capturing IgG-IC with recombinant soluble FcγRI reduced cartilage degradation [50, 51]. Given this, it is of interest to investigate the effect of osteoclast specific anti-FcγRI blocking antibodies in combination with anti-inflammatory treatment options (Fig. 3.5).

Besides being a direct target, FcγRI is also widely used as early biomarker for disease detection and prediction of disease outcome for sepsis, HIV, pediatric and adult Crohn's Disease, and tuberculosis [87–92]. The FcγRI expression levels were significantly elevated on neutrophils in patients [87–90] and macrophages in *in vivo* models [91]. These data suggest an important role for FcγRI and it could be interesting to examine if blocking FcγRI in these settings could improve the disease outcome.

Neuropathy and pain

Chronic pain is a widespread condition that affects 20% of adults in Western countries [93, 94]. Some chronic pain disorders, such as arthritis, are characterized by persistent peripheral nociceptive feedback linked to peripheral inflammation, while others, such as neuropathic pain, are the result of irregular nervous system functioning due to injury or disease [95].

IgG-IC/FcγRI signaling has been linked to both the pathogenesis [50, 66, 83] and disease-associated pain [8, 52, 53] in RA. Joint pain is a prominent clinical characteristic of RA, which is caused in part by synovitis and joint destruction [96]. While RA pain is commonly thought to be caused by inflammation, it often continues even after inflammation has been controlled with available therapies, implying the involvement of non-inflammatory mechanisms. FcγRI, but not FcγRII or FcγRIII, has been shown to be expressed in

subsets of nociceptive dorsal root ganglion (DRG) neurons in rats and mice [97, 98]. Activation of neuronal FcγRI in rat DRG neurons by ICs, raises intracellular calcium levels by activating the non-selective cation channel TRPC3 through the Syk-PLC-IP3 pathway, thereby increasing neuronal excitability [97, 99]. Hence, IgG-IC accumulation in the inflamed joint is sufficient to directly stimulate and sensitize joint sensory neurons through neuronal FcγRI, resulting in joint pain. Direct FcγRI blockade with neutralizing antibodies and FcγRI genetic knockout substantially reduced pain-related behaviors in the AIA mouse model [52, 53]. These findings suggest that FcγRI can contribute to arthritis pain through a non-inflammatory mechanism, making it a promising therapeutic target in RA patients with pain refractory to current anti-inflammatory treatments (Fig. 3.6).

Tumor targeting with antibodies

Therapeutic mAbs are designed to recognize antigens on tumor cells and mediate anti-tumor effects via various direct Fab-mediated and indirect Fc-mediated mechanisms. Direct mechanisms include inducing receptor internalization and degradation, directly inducing pro-apoptotic signals, and blocking the ligand binding site of growth factor receptors [100–102]. Indirect effects include IgG-mediated activation of the classical complement pathway, which results in complement-dependent cytotoxicity (CDC), and FcγR engagement, which results in ADCC of tumor cells [103–105]. The recruitment of cytotoxic effector cells, such as natural killer (NK) cells, monocytes/macrophages, and polymorphonuclear (PMN) cells mediates ADCC. The Fab-arms of mAbs can recognize and bind to only one unique epitope, whereas bispecific antibodies (bsAbs) can simultaneously bind two different and unique antigens, attributing dual functionalities.

Some therapeutic bsAbs were developed to act as a bridge between cytotoxic effector cells expressing FcγRI and tumor-target-overexpressing malignant cells [106, 107] (Fig. 3.II). FcγRI expression is restricted mainly to cytotoxic immune cells such as monocytes, macrophages, and cytokine-stimulated PMNs. As a result, tumor cells bound with bsAbs can be selectively detected by effector cells with cytotoxic potential. Multiple studies have shown the potential of FcγRI in anti-cancer therapy by using bsAbs and fusion proteins to recruit FcγRI on immune cells to tumor-associated-antigens on various tumor cell types including acute myeloid leukemia, acute, and chronic myelomonocytic leukemia and melanoma [9, 16, 54, 108, 109].

FcγRIs are highly potent triggering molecules to activated PMNs and, in the presence of mAbs that bind FcγRI outside the ligand binding domain, it can mediate lysis of various tumors [106]. A humanized mAb that can bind outside of the Fc-region of FcγRI is H22. As a result, serum IgG has no effect on H22 binding to FcγRI [110]. In the presence of human IgG or serum, bispecific molecules derived from H22 and coupled to tumor-specific antibodies like HER2/neu and TAG-72 or other ligands will trigger lysis of target cells [54–56]. Interestingly, the ADCC activity of the bsAb is significantly higher than that of the mAb alone [56, 106]. Experiments in murine tumor models using bsAbs that target tumor cells and FcγRI also demonstrate the potent effector functions of FcγRI [16, 106]. In some cases, FcγRI-based bsAb could establish long-term T-cell immunity [106]. Since these bsAbs can bind FcγRI in the presence of saturating concentrations of IgG [16, 110], they can effectively exploit the cytotoxic

potential of FcγRI under physiological conditions [16, 54]. It should be noted that most of these studies into FcγRI bsAbs were performed more than two decades ago. Only recently research into FcγRI targeting has revived, as the role of FcγRI in several diseases is becoming increasingly clear. Moreover, the recent developments regarding designing and producing bsAbs resulted in better and more stable bsAbs [107], making it easier to study FcγRI tumor targeting. After selecting the appropriate tumor target and anti-FcγRI mAb when developing novel bsAbs, they could become valuable tools in effective tumor destruction [54–56, 106, 111].

Additionally, cytokine stimulation could be a promising addition to anti-tumor therapeutic antibodies to enhance the activity of FcγRI-expressing immune cells [12] (Fig. 3.I). The efficacy of various therapeutic antibodies was increased when combined with cytokine stimulation both *in vitro* and *in vivo* [15, 112, 113]. Some cytokines, like granulocyte colony-stimulating factor (G-CSF), are associated with increased FcγRI expression on neutrophils and increased recruitment of effector cells [54, 114]. However, these processes take several hours or even days. Inside-out signaling of FcγRI to enhance FcγRI-IC binding occurs rapidly, within minutes [14]. Cytokine stimulation combined with antibody therapy may increase the binding capacity of FcγRI-expressing cells to tumor cells immediately after cytokine administration (minutes), while increasing FcγRI expression and recruiting more effector cells from the bone marrow occurs later (hours or days). This may result in more effective anti-tumor responses, especially when timing of cytokine administration correctly. Understanding the regulatory mechanisms of FcγRI activation may aid in the manipulation of immune responses using cytokines during infections, autoimmune diseases, and antibody-based immunotherapy.

Limitations

The use of mAbs directed against the IgG binding site of FcγRI, which block IC binding and subsequent cell activation, is the most direct way to inhibit or modulate FcγRI signaling. Mouse anti-human FcγRI antibodies to inhibit FcγRI ligand binding have been developed [19], but these antibodies may not be FcγRI-specific blocking antibodies as they bind via their Fc domain rather than their Fab domain or outside of the ligand binding domain of FcγRI [23, 52, 115, 116]. The current commercially available FcγRI blocking antibodies include clones 10.1 (mIgG1), m22 (mIgG1), and 197 (mIgG2a). Clone 10.1 is the most commonly used commercial antibody [19, 23], but it is not directly a ligand binding blocking antibody as the binding site of 10.1 is located in EC3 of FcγRI [23], while the IgG binding site is located in EC2 (17) (Fig. 2). Our own unpublished data indicates that 10.1 can achieve ~40% IgG blocking at saturating antibody concentrations, indicating it can probably sterically hinder IgG binding to FcγRI to some extent. Hence, there is a need to develop specific FcγRI blocking antibodies. However, this is difficult as the Fc portion of IgG antibodies will readily bind with high affinity to FcγRI, making screening for potential candidates very challenging. To our knowledge, no specific and high affinity Fab-mediated FcγRI blocking antibodies are currently available. Alternative strategies to block FcγRI are using an IgG Fc-fragment preparation or intravenous administration of pooled human immunoglobulin (IVIg) [64, 117]. Indeed, in pediatric ITP patients, IVIg results in rapid recovery of platelet counts [118].

Another promising strategy in autoimmune diseases is to target the ICs rather than FcγRI. Recombinant soluble FcγRs can be used to 'capture' circulating ICs and subsequently prevent binding to surface-bound FcγRs [50, 51] (Fig. 3.III). Normally, recombinant soluble ectodomains of FcγRI will be expected to be rapidly and fully occupied by circulating IgG. Surprisingly, *in vivo* mouse experiments revealed that soluble FcγRI is effective at alleviating IC-induced inflammation in antibody-dependent models of tissue damage, including CIA [50, 51]. The 'on' and 'off' rates of monomeric IgG are fast enough to enable recombinant soluble FcγRI to interact with high concentrations of oligomeric ICs in tissues, which may retain soluble FcγRI locally long enough to effectively inhibit inflammatory cell activation through IC binding to cell surface-bound FcγRI [4]. However, since FcγRI can bind to more than one IgG subclass, it would act more as a universal inhibitor of ICs. Another constraint to use soluble FcγRI is its small molecular size (45 kDa), resulting in fast renal clearance [64]. It also makes it difficult to achieve high enough FcγRI therapeutic concentrations at the site of inflammation to be effective.

The combination of therapeutic antibodies with cytokines has great potential due to the potent pro-inflammatory effects and induction of FcγRI inside-out signaling. However, there are only a few clinical trials currently investigating anti-tumor mAb therapy with cytokines [119–121]. In these studies, there are often no control groups receiving monotherapy (either mAb or cytokine), for good ethical reasons. This does make it difficult to determine the effect of cytokine stimulation on mAb therapy in humans. Nonetheless, the results of these studies are very promising. Adding G-CSF to mAb therapy in relapsed leukemia patients produced good therapy responses for a short duration [119, 120]. Before stem cell transplantation, patients receive anti-thymocyte globulin (ATG), an infusion of horse- or rabbit-derived antibodies against human T cells and the precursor thymocytes that leads to depletion of T-cells by inducing CDC and ADCC. When ATG is combined with G-CSF infusion in these patients, neutrophil-mediated ATG cytotoxicity was significantly higher, thereby enhancing T-cell clearance [122]. Furthermore, the addition of G-CSF to ATG treatment in anemia patients resulted in reduced inflammation and days of hospitalization in the first three months [123], although it does not improve the long-term outcome and sustainability of remission [124].

Directly evaluating the influence of FcγRI inside-out signaling on therapeutic antibody therapy remains challenging, as it is difficult to determine the activation status of FcγRI, and the surface expression of FcγRI is often not measured in clinical trials. In addition, inside-out signaling is a rapid process which occurs minutes after cytokine stimulation, while clinical trials usually focus on long term effects of antibody therapy. Nonetheless, the *in vitro* and *in vivo* data on inside-out signaling is very promising in regard to enhancing FcγRI effector functions.

Concluding remarks & outlook

Therapeutic antibodies can exploit FcγR-mediated effector functions and targeting FcγRI is a promising strategy to enhance the efficacy of antibody-based therapy (Fig. 3). FcγRI plays an important role in mAb based therapy [5, 7, 12], and through antibody engineering, activating, or inhibitory immunomodulatory effector functions of FcγRI can be initiated [16, 54–56, 106]. Moreover, in various autoimmune

diseases, antigens and autoantibodies cross-link and form ICs that bind and activate FcγRI [67]. These inflammatory effector functions can cause extensive tissue damage in diseases like RA and SLE, but also chronic joint pain [52, 53]. In these autoimmune diseases, blocking IC-FcγRI interactions with mAbs that specifically block the ligand binding domain of FcγRI may be beneficial.

Using anti-FcγRI/ anti-tumor bsAbs is an attractive alternative to conventional mAbs for direct tumor killing as they exhibit dual specificity for the target and effector cells. They can be designed to recruit a range of cellular effectors, like T cells and NK cells [106, 107]. If these bsAbs bind an epitope outside of the ligand binding domain of FcγRI, there is no competition with human IgG, thus ADCC activity can be attained under normal serum conditions [16, 54]. Additionally, this design would make it possible for IgG to still mediate its function by binding with its Fc-tail to FcγRI [16]. Together, these bsAbs can result in optimal tumor killing.

In conclusion, the involvement of FcγRI in many inflammatory diseases makes FcγRI a promising target in treatment of autoimmune and malignant diseases. A better understanding of inside-out signaling in combination with antibody therapy will lead to better and safer therapies.

Acknowledgements

Author contributions

Overview of author contribution to this review: T.H. Conceptualization, Visualization, Writing—Original draft, Writing—Review & editing. K.B. Conceptualization, Writing—Review & editing, Supervision. A.B. Writing—Review & editing. J.L. Conceptualization, Writing—Review & editing, Supervision.

Funding

Conflict of interest

The authors have no conflicts of interest to disclose.

Ethical approval

Not applicable.

Data availability

No new data were generated or analyzed in support of this research.

References

1. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. *Nat Rev Immunol* 2008;8(8):34–47. http://doi.org/10.1038/nri2206

2. Takai T. Fc receptors and their role in immune regulation and autoimmunity. *J Clin Immunol* 2005;25(1):1–18. http://doi.org/10.1007/s10875-005-0353-8

3. Groselj-Grenc M, Ihan A, Derganc M. Neutrophil and monocyte CD64 and CD163 expression in critically ill neonates and children with sepsis: comparison of fluorescence intensities and calculated indexes. *Mediat Inflamm* 2008;2008. http://doi.org/10.1155/2008/202646

4. Bruhns P, Iannascoli B, England P et al. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. *Blood* 2009;113(16):3716–25. http://doi.org/10.1182/blood-2008-09-179754

5. Barnes N, Gavin AL, Tan PS et al. FcγRI-deficient mice show multiple alterations to inflammatory and immune responses. *Immunity* 2002;16(3):379–89. http://doi.org/10.1016/S1074-7613(02)00287-X

6. Ioan-Facsinay A, De Kimpe SJ, Hellwig SMM et al. FcγRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. *Immunity* 2002;16(3):391–402. http://doi.org/10.1016/S1074-7613(02)00294-7

7. Bevaart L, Jansen MJH, Van Vugt MJ et al. The high-affinity IgG receptor, FcγRI, plays a central roleb in antibody therapy of experimental melanoma. *Cancer Res* 2006;66(3):1261–4. http://doi.org/10.1158/0008-5472.CAN-05-2856

8. Liang Y, Zhang Z, Juan Z et al. The high-affinity IgG receptor FcγRI modulates peripheral nerve injury-induced neuropathic pain in rats. *Mol Brain* 2019;12(1):10–3. http://doi.org/10.1186/s13041-019-0499-3

9. Boross P, Jansen JHM, van Tetering G et al. Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcgammaRI transgenic mice. *Immunol Lett* 2014;160(2):151–7. http://doi.org/10.1016/j.imlet.2014.02.005

10. Van Der Poel CE, Karssemeijer RA, Boross P et al. Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG. *Blood* 2010;116(24):5327–33. http://doi.org/10.1182/blood-2010-04-280214

11. Springer TA, Dustin ML. Integrin inside-out signaling and the immunological synapse. *Curr Opin Cell Biol* 2012;24(1):107–15. http://doi.org/10.1016/j.ceb.2011.10.004

12. Brandsma AM, Jacobino SR, Meyer S et al. Fc receptor inside-out signaling and possible impact on antibody therapy. *Immunol Rev* 2015;268(1):74–87. http://doi.org/10.1111/imr.12332

13. Bakema JE, Bakker A, de Haij S et al. Inside-out regulation of Fc alpha RI (CD89) depends on PP2A. *J Immunol* 2008;181(6):4080–8. http://doi.org/10.4049/jimmunol.181.6.4080

14. Brandsma AM, Schwartz SL, Wester MJ et al. Mechanisms of inside-out signaling of the high-affinity IgG receptor FcγRI. *Sci Signal* 2018;11(540). http://doi.org/10.1126/scisignal.aaq0891

15. Valerius T, Repp R, de Wit TP et al. Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. *Blood* 1993;82(3):931–9. https://pubmed.ncbi.nlm.nih.gov/9548506/

16. Heijnen IA, Rijks LJ, Schiel A et al. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies. *J Immunol* 1997;159(11):5629–39. https://pubmed.ncbi.nlm.nih.gov/9548506/

17. Kiyoshi M, Caaveiro JMM, Kawai T et al. Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI. *Nat Commun* 2015;6:6866. http://doi.org/10.1038/ncomms7866

18. Temming AR, Bentlage A, de Taeye S et al. Cross-reactivity of mouse IgG subclasses to human Fc gamma receptors: antibody deglycosylation only eliminates IgG2b binding. *Mol Immunol* 2020;127:79–86. http://doi.org/10.1016/j.molimm.2020.08.015

19. Dougherty GJ, Selvendran Y, Murdoch S et al. The human mononuclear phagocyte high-affinity Fc receptor, FcRI, defined by a monoclonal antibody, 10.1. *Eur J Immunol* 1987;17(10):1453–9. http://doi.org/10.1002/eji.1830171011

20. Mancardi DA, Albanesi M, Jönsson F et al. The high-affinity human IgG receptor FcγRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy. *Blood* 2013;121(9):1563–73. http://doi.org/10.1182/blood-2012-07-442541

21. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. *Blood* 2012;119(24):5640–9. http://doi.org/10.1182/blood-2012-01-380121

22. Dekkers G, Bentlage AEH, Stegmann TC et al. Affinity of human IgG subclasses to mouse Fc gamma receptors. *MAbs [Internet]* 2017;9(5):767–73. http://doi.org/10.1080/19420862.2017.1323159

23. Harrison PT, Allen JM. High affinity IgG binding by FcgammaRI (CD64) is modulated by two distinct IgSF domains and the transmembrane domain of the receptor. *Protein Eng Des Sel [Internet]* 1998;11(3):225–32. http://doi.org/10.1093/protein/11.3.225

24. Monteiro RC. Fc receptors and cell activation. *Press Medicale [Internet]* 2013;42(4):598–9. http://dx.doi.org/10.1016/j.lpm.2013.01.035

25. Duncan AR, Woof JM, Partridge LJ et al. Localization of the binding site for the human high-affinity Fc receptor on IgG. *Nature [Internet]* 1988;332(6164):563–4. https://doi.org/10.1038/332563a0

26. Chappel MS, Isenman DE, Everett M et al. Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. *Proc Natl Acad Sci U S A [Internet]* 1991;88(20):9036–40. http://doi.org/10.1073/pnas.88.20.9036

27. Lu J, Ellsworth JL, Hamacher N et al. Crystal structure of Fcγ receptor I and its implication in high affinity γ-immunoglobulin binding. *J Biol Chem* 2011;286(47):40608–13. http://doi.org/10.1074/jbc.M111.257550

28. Lu J, Chu J, Zou Z et al. Structure of fcγri in complex with Fc reveals the importance of glycan recognition for high-affinity gG binding. *Proc Natl Acad Sci U S A* 2015;112(3):833–8. http://doi.org/10.1073/pnas.1418812112

29. Duchemin AM, Ernst LK, Anderson CL. Clustering of the high affinity Fc receptor for immunoglobulin G (Fc gamma RI) results in phosphorylation of its associated gamma-chain. *J Biol Chem [Internet]* 1994;269(16):12111–7. http://doi.org/10.1016/s0021-9258(17)32688-1

30. Harrison PT, Davis W, Norman JC et al. Binding of monomeric immunoglobulin G triggers Fc gamma RI-mediated endocytosis. *J Biol Chem* 1994;269(39):24396–402. http://doi.org/10.1016/s0021-9258(19)51097-3

31. Lux A, Yu X, Scanlan CN et al. Impact of immune complex size and glycosylation on IgG binding to human FcγRs. *J Immunol* 2013;190(8):4315–23 . http://doi.org/10.4049/jimmunol.1200501

32. van Vugt MJ, Kleijmeer MJ, Keler T et al. The FcgammaRIa (CD64) ligand binding chain triggers major histocompatibility complex class II antigen presentation independently of its associated FcR gamma-chain. *Blood* 1999;94(2):808–17. https://pubmed.ncbi.nlm.nih.gov/10397749/

33. Pan LF, Kreisle RA, Shi YD. Detection of Fcgamma receptors on human endothelial cells stimulated with cytokines tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma). *Clin Exp Immunol* 1998;112(3):533–8. http://doi.org/10.1046/j.1365-2249.1998.00597.x

34. Okun E, Mattson MP, Arumugam TV. Involvement of Fc receptors in disorders of the central nervous system. *Neuromolecular Med* 2010;12:164–78. http://doi.org/10.1007/s12017-009-8099-5

35. Fanger NA, Voigtlaender D, Liu C et al. Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fc gamma RI (CD64) expressed on human blood dendritic cells. *J Immunol* 1997;158(7):3090–8. http://www.ncbi.nlm.nih.gov/pubmed/9120261

36. Albanesi M, Mancardi DA, Macdonald LE et al. Cutting edge: FcγRIII (CD16) and FcγRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma. *J Immunol* 2012;189(12):5513–17. http://doi.org/10.4049/jimmunol.1201511

37. Getahun A, Cambier JC. Of ITIMs, ITAMs, and ITAMis: revisiting immunoglobulin Fc receptor signaling. *Immunol Rev* 2015;268(1):66–73. http://doi.org/10.1111/imr.12336

38. Nimmerjahn F, Ravetch J V. Fc-receptors as regulators of immunity. *Adv Immunol* 2007;96:179–204. http://doi.org/10.1016/S0065-2776(07)96005-8

39. Huang Z-Y, Hunter S, Kim M-K et al. The effect of phosphatases SHP-1 and SHIP-1 on signaling by the ITIM- and ITAM-containing Fcγ receptors FcγRIIB and FcγRIIA. *J Leukoc Biol* 2003;73(6):823–9. http://doi.org/10.1189/jlb.0902454

40. Cady CT, Powell MS, Harbeck RJ et al. IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcγRIIA and FcγRIIB. *Immunol Lett* 2010;130(1–2):57–65. http://doi.org/10.1038/337078a0

41. Sutterwala FS, Noel GJ, Salgame P et al. Reversal of proinflammatory responses by ligating the macrophage Fcγ receptor type I. *J Exp Med* 1998;188(1):217–22. http://doi.org/10.1084/jem.188.1.217

42. Rodriguez W, Mold C, Kataranovski M et al. C-reactive protein-mediated suppression of nephrotoxic nephritis: role of macrophages, complement, and Fcγ receptors. *J Immunol* 2007;178(1):530–38. http://doi.org/10.4049/jimmunol.178.1.530

43. Blank U, Launay P, Benhamou M et al. Inhibitory ITAMs as novel regulators of immunity. *Immunol Rev* 2009;232:59–71. http://doi.org/10.1111/j.1600-065X.2009.00832.x

44. Swisher JFA, Feldman GM. The many faces of FcγRI: implications for therapeutic antibody function. *Immunol Rev* 2015;268:160–74. http://doi.org/10.1111/imr.12334

45. Boekhoudt GH, Frazier-Jessen MR, Feldman GM. Immune complexes suppress IFN-γ signaling by activation of the FcγRI pathway. *J Leukoc Biol* 2007;81(4):1086–92. http://doi.org/10.1189/jlb.0906543

46. Van Vugt MJ, Heijnen IAFM, Capel PJA et al. FcR γ-chain is essential for both surface expression and function of human FcγRI (CD64) in vivo. *Blood* 1996;87(9):3593–9. http://doi.org/10.1182/blood.v87.9.3593.bloodjournal8793593

47. Reefman E, Horst G, Nijk MT et al. Opsonization of late apoptotic cells by systemic lupus erythematosus autoantibodies inhibits their uptake via an Fcγ receptor–dependent mechanism. *Arthritis Rheum [Internet]* 2007;56(10):3399–411. https://doi.org/10.1002/art.22947

48. Kiekens RC, Thepen T, Bihari IC et al. Expression of Fc receptors for IgG during acute and chronic cutaneous inflammation in atopic dermatitis. *Br J Dermatol* 2000;142(6):1106–13. http://doi.org/10.1046/j.1365-2133.2000.03534.x

49. Hristodorov D, Mladenov R, von Felbert V et al. Targeting CD64 mediates elimination of M1 but not M2 macrophages in vitro and in cutaneous inflammation in mice and patient biopsies. *MAbs [Internet]* 2015;7(5):853–62. http://doi.org/10.1080/19420862.2015.1066950

50. Ellsworth JL, Hamacher N, Harder B et al. Recombinant soluble human FcγR1A (CD64A) reduces inflammation in murine collagen-induced arthritis. *J Immunol* 2009;182(11):7272–9. http://doi.org/10.4049/jimmunol.0803497

51. Ellsworth JL, Maurer M, Harder B et al. Targeting immune complex-mediated hypersensitivity with recombinant soluble human FcγRIA (CD64A). *J Immunol* 2008;180(1):580–9. http://doi.org/10.4049/jimmunol.180.1.580

52. Wang L, Jiang X, Zheng Q et al. Neuronal FcγRI mediates acute and chronic joint pain. *J Clin Invest* 2019;129(9):3754–69. http://doi.org/10.1186/s13054-015-0972-z

53. Liu F, Shen X, Su S et al. Fcγ receptor I–coupled signaling in peripheral nociceptors mediates joint pain in a rat model of rheumatoid arthritis. *Arthritis Rheumatol* 2020;72(10):1668–78. http://doi.org/10.1002/art.41386

54. Keler T, Graziano RF, Mandal A et al. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells. *Cancer Res* 1997;57(18):4008–14. http://www.ncbi.nlm.nih.gov/pubmed/9307286

55. Goldstein J, Graziano RF, Sundarapandiyan K et al. Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein. *J Immunol* 1997;158(2):872–9. http://www.ncbi.nlm.nih.gov/pubmed/8993006

56. Russoniello C, Somasundaram C, Schlom J et al. Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells. *Clin Cancer Res* 1998;4(9):2237–43. http://www.ncbi.nlm.nih.gov/pubmed/9748144

57. Beekman JM, van der Linden JA, van de Winkel JGJ et al. FcgammaRI (CD64) resides constitutively in lipid rafts. *Immunol Lett* 2008;116(2):149–55. http://doi.org/10.1016/j.imlet.2007.12.003

58. van der Poel CE, Spaapen RM, van de Winkel JGJ et al. Functional characteristics of the high affinity IgG receptor, FcγRI. *J Immunol [Internet]* 2011;186(5):2699–704. http://doi.org/10.4049/jimmunol.1003526

59. Edberg JC, Qin H, Gibson AW et al. The CY domain of the FcγRIa α-chain (CD64) alters γ-chain tyrosine-based signaling and phagocytosis. *J Biol Chem* 2002;277(43):41287–93. http://doi.org/10.1074/jbc.M207835200

60. Haystead TA, Sim AT, Carling D et al. Effects of the tumour promoter okadaic acid on intracellular protein phosphorylation and metabolism. *Nature* 1989;337(6202):78–81. http://doi.org/10.1038/337078a0

61. Bissantz C. Conformational changes of G protein-coupled receptors during their activation by agonist binding. *J Recept Signal Transduct Res* 2003;23(2–3):123–53. http://doi.org/10.1081/RRS-120025192

62. Koenderman L. Inside-out control of Fc-receptors. *Front Immunol* 2019;10. http://doi.org/10.3389/fimmu.2019.00544

63. Mkaddem SB, Benhamou M, Monteiro RC. Understanding Fc receptor involvement in inflammatory diseases: from mechanisms to new therapeutic tools. *Front Immunol* 2019;10. http://doi.org/10.3389/fimmu.2019.00811

64. Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. *Nat Rev Drug Discov* 2012;11(4):311–31. http://doi.org/10.1038/nrd2909

65. Boross P, van Lent PL, Martin-Ramirez J et al. Destructive arthritis in the absence of both FcgammaRI and FcgammaRIII. *J Immunol* 2008;180(7):5083–91. http://doi.org/10.4049/jimmunol.180.7.5083

66. Van Lent PLEM, Nabbe K, Blom AB et al. Role of activatory FcγRI and FcγRIII and inhibitory FcγRII in inflammation and cartilage destruction during experimental antigen-induced arthritis. *Am J Pathol* 2001;159(6):2309–20. http://doi.org/10.1016/S0002-9440(10)63081-7

67. Clynes R, Dumitru C, Ravetch J V. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. *Science* 1998;279(5353):1052–4. http://doi.org/10.1126/science.279.5353.1052

68. McLigeyo SO. Pathogenesis of lupus nephritis: a review. *East Afr Med J* 1998;75(11):628–31. http://www.ncbi.nlm.nih.gov/pubmed/10065172

69. Di Ceglie I, Kruisbergen NNL, van den Bosch MHJ et al. Fc-gamma receptors and S100A8/A9 cause bone erosion during rheumatoid arthritis. Do they act as partners in crime? *Rheumatology* 2019;58(8):1331–43. http://doi.org/10.1093/rheumatology/kez218

70. Akinrinmade OA, Chetty S, Daramola AK et al. CD64: an attractive immunotherapeutic target for m1-type macrophage mediated chronic inflammatory diseases. *Biomedicines* 2017;5(3). http://doi.org/10.3390/biomedicines5030056

71. Ericson SG, Coleman KD, Wardwell K et al. Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes. *Br J Haematol* 1996;92(3):718–24. http://doi.org/10.1046/j.1365-2141.1996.393931.x

72. Li MO, Sarkisian MR, Mehal WZ et al. Phosphatidylserine receptor is required for clearance of apoptotic cells. *Science* 2003;302(5650):1560–3. http://doi.org/10.1126/science.1087621

73. Toschi V, Motta A, Castelli C et al. Prevalence and clinical significance of antiphospholipid antibodies to noncardiolipin antigens in systemic lupus erythematosus. *Haemostasis* 1993;23(5):275–83. http://doi.org/10.1159/000216887

74. Korb LC, Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. *J Immunol* 1997;158(10):4525–8. http://www.ncbi.nlm.nih.gov/pubmed/9144462

75. Utz PJ, Hottelet M, Schur PH et al. Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. *J Exp Med* 1997;185(5):843–54. http://doi.org/10.1084/jem.185.5.843

76. Utz PJ, Anderson P. Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens. *Arthritis Rheum* 1998;41(7):1152–60. http://doi.org/10.1002/1529-0131(199807)41:7<1152::AID-ART3>3.0.CO;2-L

77. Erwig LP, Gordon S, Walsh GM et al. Previous uptake of apoptotic neutrophils or ligation of integrin receptors downmodulates the ability of macrophages to ingest apoptotic neutrophils. *Blood* 1999;93(4):1406–12. http://doi.org/10.1182/blood.v93.4.1406.404k10_1406_1412

78. Lukács K, Kávai M, Bányai A et al. Effects of immune complexes from SLE patients on human monocyte locomotion and Fc receptor function. *Ann Rheum Dis* 1984;43(5):729–33. http://doi.org/10.1136/ard.43.5.729

79. Li Y, Lee PY, Sobel ES et al. Increased expression of FcγRI/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus. *Arthritis Res Ther* 2009;11(1):R6. http://doi.org/10.1186/ar2590

80. Heller T, Gessner JE, Schmidt RE et al. Cutting edge: Fc receptor type I for IgG on macrophages and complement mediate the inflammatory response in immune complex peritonitis. *J Immunol* 1999;162(10):5657–61. http://www.ncbi.nlm.nih.gov/pubmed/10229794

81. Li Y, Tucci M, Narain S et al. Urinary biomarkers in lupus nephritis. *Autoimmun Rev* 2006;5(6):383–8. http://doi.org/10.1016/j.autrev.2005.10.006

82. Almutairi K, Nossent J, Preen D et al. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. *Rheumatol Int [Internet]* 2021;41(5):863–77. https://doi.org/10.1007/s00296-020-04731-0

83. Van Lent PL, Grevers L, Lubberts E et al. Fcγ receptors directly mediate cartilage, but not bone, destruction in murine antigen-induced arthritis: uncoupling of cartilage damage from bone erosion and joint inflammation. *Arthritis Rheum* 2006;54(12). http://doi.org/10.1002/art.22253

84. Rombouts Y, Ewing E, van de Stadt LA et al. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. *Ann Rheum Dis [Internet]* 2015;74(1):234–41. http://doi.org/10.1136/annrheumdis-2013-203565

85. van Vuuren AJ, van Roon JAG, Walraven V et al. CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model. *J Immunol* 2006;176(10). http://doi.org/10.1158/0008-5472.CAN-05-2856

86. Grevers LC, De Vries TJ, Everts V et al. Immune complex-induced inhibition of osteoclastogenesis is mediated via activating but not inhibitory Fcγ receptors on myeloid precursor cells. *Ann Rheum Dis* 2013;72(2). http://doi.org/10.1136/annrheumdis-2012-201568

87. Therrien A, Chapuy L, Bsat M, Rubio M et al. Recruitment of activated neutrophils correlates with disease severity in adult Crohn's disease. *Clin Exp Immunol* 2019;195(2):251–64. http://doi.org/10.1111/cei.13226

88. Minar P, Jackson K, Tsai YT et al. Validation of neutrophil CD64 blood biomarkers to detect mucosal inflammation in pediatric Crohn's disease. *Inflamm Bowel Dis* 2018;24(1):198–208. http://doi.org/10.1093/ibd/izx022

89. Wang X, Li Z-Y, Zeng L et al. Neutrophil CD64 expression as a diagnostic marker for sepsis in adult patients: a meta-analysis. *Crit Care* 2015;19(1):245. http://doi.org/10.1186/s13054-015-0972-z

90. Hoffmann JJML. Neutrophil CD64: a diagnostic marker for infection and sepsis. *Clin Chem Lab Med* 2009;47(8):903–16. http://doi.org/10.1515/CCLM.2009.224

91. Montefiori DC, Filsinger Interrante MV, Bell BN et al. The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat. *Proc Natl Acad Sci U S A* 2021;118(3). http://doi.org/10.1073/pnas.2018027118

92. Corrêa RDS, Rodrigues LS, Pereira LHL et al. Neutrophil CD64 expression levels in IGRA-positive individuals distinguish latent tuberculosis from active disease. *Mem Inst Oswaldo Cruz* 2019;114(2):e180579. http://doi.org/10.1590/0074-02760180579

93. Breivik H, Eisenberg E, O'Brien T. The individual and societal burden of chronic pain in Europe: the case for strategic prioritisation and action to improve knowledge and availability of appropriate care. *BMC Public Health* 2013;13:1229. http://doi.org/10.1186/1471-2458-13-1229

94. Dahlhamer J, Lucas J, Zelaya C et al. Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016. *Morb Mortal Wkly Rep* 2018;67(36):1001–6. http://doi.org/10.15585/mmwr.mm6736a2

95. Grace PM, Tawfik VL, Svensson CI et al. The neuroimmunology of chronic pain: from rodents to humans. *J Neurosci [Internet]* 2021;41(5):855–65. http://doi.org/10.1523/JNEUROSCI.1650-20.2020

96. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. *N Engl J Med* 2011;365(23):2205–19. http://doi.org/10.1056/NEJMra1004965

97. Qu L, Zhang P, LaMotte RH et al. Neuronal Fc-gamma receptor I mediated excitatory effects of IgG immune complex on rat dorsal root ganglion neurons. *Brain Behav Immun* 2011;25(7):1399–407. http://doi.org/10.1016/j.bbi.2011.04.008

98. Andoh T, Kuraishi Y. Direct action of immunoglobulin G on primary sensory neurons through Fc gamma receptor I. *FASEB J* 2004;18(1):182–4. http://doi.org/10.1096/fj.02-1169fje

99. Qu L, Li Y, Pan X et al. Transient receptor potential canonical 3 (TRPC3) is required for IgG immune complex-induced excitation of the rat dorsal root ganglion neurons. *J Neurosci* 2012;32(28):9554–62. http://doi.org/10.1523/JNEUROSCI.6355-11.2012

100. Reslan L, Dalle S, Herveau S et al. Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. *Leuk Lymphoma* 2014;55(1):188–90. http://doi.org/10.3109/10428194.2013.788175

101. Klapper LN, Waterman H, Sela M et al. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. *Cancer Res* 2000;60(13):3384–8. http://www.ncbi.nlm.nih.gov/pubmed/10910043

102. Goldstein NI, Prewett M, Zuklys K et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. *Clin Cancer Res* 1995;1(11):1311–8. http://www.ncbi.nlm.nih.gov/pubmed/9815926

103. Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. *Semin Cancer Biol* 2012;22(1):3–13. http://doi.org/10.1016/j.semcancer.2011.12.009

104. Bindon CI, Hale G, Brüggemann M et al. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. *J Exp Med* 1988;168(1):127–42. http://doi.org/10.1084/jem.168.1.127

105. Meyer S, Leusen JHW, Boross P. Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. *MAbs* 2014;6(5):1133–44. http://doi.org/10.4161/mabs.29670

106. Honeychurch J, Tutt AL, Valerius T et al. Therapeutic efficacy of FcgammaRI/CD64-directed bispecific antibodies in B-cell lymphoma. *Blood* 2000;96(10):3544–52. http://doi.org/10.1182/blood.v96.10.3544.h8003544_3544_3552

107. Klein C, Schaefer W, Regula JT. The use of CrossMAb technology for the generation of bi- and multispecific antibodies. *mAbs* 2016;8:1010–20. http://doi.org/10.1080/19420862.2016.1197457

108. Akinrinmade OA, Jordaan S, Hristodorov D et al. Human MAP Tau based targeted cytolytic fusion proteins. *Biomedicines* 2017;5(3). https://doi.org/10.3390/biomedicines5030036

109. Mladenov R, Hristodorov D, Cremer C et al. CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo. *Oncotarget* 2016;7(41):67166–74. http://doi.org/10.18632/oncotarget.11568

110. Graziano RF, Tempest PR, White P et al. Construction and characterization of a humanized anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody. *J Immunol* 1995;155(10):4996–5002. http://www.ncbi.nlm.nih.gov/pubmed/7594506

111. Bevaart L, Goldstein J, Vitale L et al. Direct targeting of genetically modified tumour cells to FcγRI triggers potent tumour cytotoxicity. *Br J Haematol [Internet]* 2006;132(3):317–25. https://doi.org/10.1111/j.1365-2141.2005.05884.x

112. Kushner BH, Cheung NK. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. *Blood* 1989;73(7):1936–41. http://doi.org/10.1182/blood.v73.7.1936.1936

113. Molfetta R, Quatrini L, Gasparrini F et al. Regulation of fc receptor endocytic trafficking by ubiquitination. *Front Immunol* 2014;5:449. http://doi.org/10.3389/fimmu.2014.00449

114. Würflein D, Dechant M, Stockmeyer B et al. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. *Cancer Res* 1998;58(14):3051–8. http://www.ncbi.nlm.nih.gov/pubmed/9679970

115. Unkeless JC. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. *J Exp Med* 1979;150(3):580–96. http://doi.org/10.1084/jem.150.3.580

116. Guyre PM, Graziano RF, Vance BA et al. Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function. *J Immunol* 1989;143(5):1650–5. http://www.ncbi.nlm.nih.gov/pubmed/2474608

117. Nagelkerke SQ, Dekkers G, Kustiawan I et al. Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages. *Blood [Internet]* 2014;124(25):3709–18. https://doi.org/10.1182/blood-2014-05-576835

118. Debré M, Griscelli C, Bonnet M-C, Carosella E et al. Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura. *Lancet [Internet]* 1993;342(8877):945–9. http://doi.org/10.1016/0140-6736(93)92000-J

119. van der Kolk LE, Grillo-López AJ, Baars JW et al. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. *Leukemia* 2003;17(8):1658–64. http://doi.org/10.1038/sj.leu.2402995

120. Gorin N-C, Isnard F, Garderet L et al. Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study. *Eur J Haematol* 2013;91(4):315–21. http://doi.org/10.1111/ejh.12154

121. Cohen JB, Bucur S, Winton EF et al. Combination of GM-CSF with fludarabine-containing regimens in chronic lymphocytic leukemia and indolent non-hodgkin lymphoma. *Clin Lymphoma Myeloma Leuk* 2015;15(9):514–8. http://doi.org/10.1016/j.clml.2015.06.009

122. de Koning C, Gabelich J-A, Langenhorst J et al. Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation. *Blood Adv* 2018;2(5):565–74. http://doi.org/10.1182/bloodadvances.2017015487

123. Tichelli A, Schrezenmeier H, Socié G et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. *Blood [Internet]* 2011;117(17):4434–41. https://doi.org/10.1182/blood-2010-08-304071

124. Tichelli A, de Latour RP, Passweg J et al. Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party. *Haematologica [Internet]* 2020;105(5):1223–31. http://doi.org/10.3324/HAEMATOL.2019.222562